

Programmi Uso Terapeutico Compassionevole	Promotore	Data Parere Unico CE	Documenti
Ruxolitinib Managed Access Program (MAP) for patients diagnosed with COVID19 and have severe/very severe lung disease (CINC424, RUXOLITINIB, JAKAVI)	Novartis	02/04/2020	https://www.aifa.gov.it/documents/20142/1140695/Ruxolitinib_documenti.zip
Managed Access Program (MAP) to provide access to canakinumab treatment of cytokine release syndrome (CRS) in patients with COVID-19-induced pneumonia (CANAKINUMAB, ILARIS)	Novartis	07/04/2020	https://www.aifa.gov.it/documents/20142/1143282/Canakinumab_documenti.zip